156 related articles for article (PubMed ID: 9305716)
1. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin.
Jonas S; Rayes N; Neumann U; Neuhaus R; Bechstein WO; Guckelberger O; Tullius SG; Serke S; Neuhaus P
Cancer; 1997 Sep; 80(6):1141-50. PubMed ID: 9305716
[TBL] [Abstract][Full Text] [Related]
2. A prospective randomized trial comparing interleukin-2 receptor antibody versus antithymocyte globulin as part of a quadruple immunosuppressive induction therapy following orthotopic liver transplantation.
Langrehr JM; Nüssler NC; Neumann U; Guckelberger O; Lohmann R; Radtke A; Jonas S; Klupp J; Steinmüller T; Lobeck H; Meuer S; Schlag H; Lemmens HP; Knoop M; Keck H; Bechstein WO; Neuhaus P
Transplantation; 1997 Jun; 63(12):1772-81. PubMed ID: 9210503
[TBL] [Abstract][Full Text] [Related]
3. Rejection episodes after liver transplantation during primary immunosuppression with FK506 or a cyclosporine-based regimen: a controlled, prospective, randomized trial.
Jonas S; Kling N; Bechstein WO; Blumhardt G; Lohmann R; Lobeck H; Neuhaus P
Clin Transplant; 1995 Oct; 9(5):406-14. PubMed ID: 8541635
[TBL] [Abstract][Full Text] [Related]
4. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients.
Charpentier B; Rostaing L; Berthoux F; Lang P; Civati G; Touraine JL; Squifflet JP; Vialtel P; Abramowicz D; Mourad G; Wolf P; Cassuto E; Moulin B; Rifle G; Pruna A; Merville P; Mignon F; Legendre C; Le Pogamp P; Lebranchu Y; Toupance O; Hurault De Ligny B; Touchard G; Olmer M; Purgus R; Pouteil-Noble C; Glotz D; Bourbigot B; Leski M; Wauters JP; Kessler M
Transplantation; 2003 Mar; 75(6):844-51. PubMed ID: 12660513
[TBL] [Abstract][Full Text] [Related]
5. Primary immunosuppression with tacrolimus after liver transplantation: 12-years follow-up.
Jonas S; Neuhaus R; Junge G; Klupp J; Theruvat T; Langrehr JM; Settmacher U; Neuhaus P
Int Immunopharmacol; 2005 Jan; 5(1):125-8. PubMed ID: 15589470
[TBL] [Abstract][Full Text] [Related]
6. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients.
Wimmer CD; Angele MK; Schwarz B; Pratschke S; Rentsch M; Khandoga A; Guba M; Jauch KW; Bruns C; Graeb C
Transpl Int; 2013 Oct; 26(10):999-1006. PubMed ID: 23952102
[TBL] [Abstract][Full Text] [Related]
7. Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation.
Cantarovich D; Karam G; Giral-Classe M; Hourmant M; Dantal J; Blancho G; Le Normand L; Soulillou JP
Kidney Int; 1998 Oct; 54(4):1351-6. PubMed ID: 9767555
[TBL] [Abstract][Full Text] [Related]
8. Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety.
Kyllönen LE; Eklund BH; Pesonen EJ; Salmela KT
Transplantation; 2007 Jul; 84(1):75-82. PubMed ID: 17627241
[TBL] [Abstract][Full Text] [Related]
9. De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients.
Gruber SA; Gillingham K; Sothern RB; Stephanian E; Matas AJ; Dunn DL
Clin Transplant; 1994 Aug; 8(4):388-95. PubMed ID: 7949545
[TBL] [Abstract][Full Text] [Related]
10. Lymphoproliferative disorders after renal transplantation in patients receiving triple or quadruple immunosuppression.
Melosky B; Karim M; Chui A; McBride M; Cameron EC; Yeung CK; Landsberg D; Shackleton C; Keown PA
J Am Soc Nephrol; 1992 Jun; 2(12 Suppl):S290-4. PubMed ID: 1323341
[TBL] [Abstract][Full Text] [Related]
11. A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation.
Langrehr JM; Glanemann M; Guckelberger O; Klupp J; Neumann U; Machens C; Lohmann R; Knoop M; Lobeck H; Schlag H; Keck H; Settmacher U; Bechstein WO; Neuhaus PJ
Clin Transplant; 1998 Aug; 12(4):303-12. PubMed ID: 9686324
[TBL] [Abstract][Full Text] [Related]
12. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus.
Levy G; Grazi GL; Sanjuan F; Wu Y; Mühlbacher F; Samuel D; Friman S; Jones R; Cantisani G; Villamil F; Cillo U; Clavien PA; Klintmalm G; Otto G; Pollard S; McCormick PA
Liver Transpl; 2006 Oct; 12(10):1464-72. PubMed ID: 17004259
[TBL] [Abstract][Full Text] [Related]
13. Results of lis2t, a multicenter, randomized study comparing cyclosporine microemulsion with C2 monitoring and tacrolimus with C0 monitoring in de novo liver transplantation.
Levy G; Villamil F; Samuel D; Sanjuan F; Grazi GL; Wu Y; Marotta P; Boillot O; Muehlbacher F; Klintmalm G;
Transplantation; 2004 Jun; 77(11):1632-8. PubMed ID: 15201658
[TBL] [Abstract][Full Text] [Related]
14. Tacrolimus in pancreas transplantation: a multicenter analysis. Tacrolimus Pancreas Transplant Study Group.
Gruessner RW
Clin Transplant; 1997 Aug; 11(4):299-312. PubMed ID: 9267719
[TBL] [Abstract][Full Text] [Related]
15. Quadruple tacrolimus-based induction therapy including azathioprine and ALG does not significantly improve outcome after liver transplantation when compared with standard induction with tacrolimus and steroids: results of a prospective, randomized trial.
Neuhaus P; Klupp J; Langrehr JM; Neumann U; Gebhardt A; Pratschke J; Tullius SG; Lohmann R; Radke C; Rayes N; Neuhaus R; Bechstein WO
Transplantation; 2000 Jun; 69(11):2343-53. PubMed ID: 10868638
[TBL] [Abstract][Full Text] [Related]
16. Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients.
Nashan B; Schlitt HJ; Schwinzer R; Ringe B; Kuse E; Tusch G; Wonigeit K; Pichlmayr R
Transplantation; 1996 Feb; 61(4):546-54. PubMed ID: 8610379
[TBL] [Abstract][Full Text] [Related]
17. REFINE: a randomized trial comparing cyclosporine A and tacrolimus on fibrosis after liver transplantation for hepatitis C.
Levy G; Villamil FG; Nevens F; Metselaar HJ; Clavien PA; Klintmalm G; Jones R; Migliaccio M; Prestele H; Orsenigo R;
Am J Transplant; 2014 Mar; 14(3):635-46. PubMed ID: 24456049
[TBL] [Abstract][Full Text] [Related]
18. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation.
Hasenbein W; Albani J; Englert C; Spehr A; Grabhorn E; Kemper MJ; Burdelski M; Ganschow R
Pediatr Transplant; 2006 Dec; 10(8):938-42. PubMed ID: 17096762
[TBL] [Abstract][Full Text] [Related]
19. Quadruple induction therapy including antithymocyte globulin or interleukin-2 receptor antibody or FK 506-based induction therapy after liver transplantation.
Lohmann R; Langrehr JM; Klupp J; Neumann U; Guckelberger O; Müller AR; Nüssler NC; Jonas S; Lang M; Settmacher U; Bechstein WO; Neuhaus PJ
Transplant Proc; 1999; 31(1-2):380. PubMed ID: 10083151
[No Abstract] [Full Text] [Related]
20. Analysis of malignancies in patients after heart transplantation with subsequent immunosuppressive therapy.
Rivinius R; Helmschrott M; Ruhparwar A; Schmack B; Klein B; Erbel C; Gleissner CA; Akhavanpoor M; Frankenstein L; Darche FF; Thomas D; Ehlermann P; Bruckner T; Katus HA; Doesch AO
Drug Des Devel Ther; 2015; 9():93-102. PubMed ID: 25552900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
